AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

NCT03959891 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

77

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Ipatasertib
DRUG: Fulvestrant
DRUG: Aromatase Inhibitor
DRUG: Palbociclib

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]